stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
51.90
3.44
+7.10%
Follow MBX
Alert me
MBX Biosciences, Inc. (MBX) Return on assets
MBX Biosciences, Inc.'s return on assets over the twelve months to 30 June 2026 was −31.3%, down 4.6 percentage points from fiscal 2025 (−26.6%). That is above the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −26.6% | 8.50 |
| FY2024 | −35.1% | 15.27 |
| FY2023 | −50.4% | (50.38) |
| FY2022 | 0.00% | — |
Return on assets against peers
| Company | Return on assets |
|---|---|
| ADMA ADMA Biologics Inc compare | 28.0% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −18.2% |
| XNCR Xencor, Inc. compare | −20.4% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −27.8% |
| MBX MBX Biosciences, Inc. | −31.3% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −36.3% |
| CLDX Celldex Therapeutics, Inc. compare | −40.8% |
| RCUS Arcus Biosciences, Inc. compare | −50.6% |
| PHVS Pharvaris N.V. compare | −64.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)